Pharmos announces results of its Phase 2b Dextofisopam trial

Pharmos Corporation (Pink Sheets: PARS); on September 14, 2009, Pharmos announced the results of its Phase 2b Dextofisopam trial for the treatment of diarrhea predominant and alternating diarrhea and constipation irritable bowel syndrome. While the results did not achieve statistical significance for the primary endpoint of overall adequate relief due to an unexpectedly high placebo response rate, the drug clearly showed activity, especially at the 200 mg dose level, confirming the efficacy seen in the Phase 2a trial. In addition, Dextofisopam was well-tolerated across all doses.

Dextofisopam is one of the most advanced compounds currently in clinical development for the treatment of IBS-d and IBS-a. Pharmos has engaged Cowen and Company to assist the Company with its previously communicated strategy of entering into a partnership for further development of Dextofisopam.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Acute gastroenteritis linked to higher rates of irritable bowel syndrome and functional dyspepsia